Management of metallo-β-lactamase-producing Enterobacterales infections: a modified Delphi study
JAC-Antimicrobial Resistance · 07.01.2026 · 8 (1)
DOI: 10.1093/jacamr/dlag030 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 02.03.2026. Verfasst von Yehuda Carmeli und 13 weiteren Autor:innen. Beteiligte Einrichtung: The National Institute of Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Inc..
Abstract (Originalsprache)
Background and objectives Metallo-β-lactamase (MBL)-producing Enterobacterales infections are an urgent global healthcare problem with limited treatment options. To obtain greater understanding of international perspectives on optimal management of serious infections due to MBL-producing Enterobacterales, we used a modified Delphi process to elicit experts’ opinion and establish consensus.
Methods
A Delphi panel comprising 10 expert physicians experienced in antimicrobial-resistant bacterial infection management were surveyed on epidemiology, disease, testing and management of MBL-producing Enterobacterales infections. Consensus statements were based on survey responses and reviewed by the panel for endorsement or revisions to achieve consensus during a virtual meeting.
Results
All panellists acknowledged MBL-producing Enterobacterales as a key source of antimicrobial resistance and infection in most countries. All agreed these infections have high morbidity and mortality, leading to the need for critical-level care, longer hospital stays and significant healthcare costs. The negative clinical and economic consequences of MBL-producing Enterobacterales are compounded by inappropriate use of multidrug antimicrobial regimens. Therefore, a specific MBL-targeting agent is considered desirable. When aztreonam-avibactam and cefiderocol are available, the preferred first-line treatment is aztreonam-avibactam, per in vitro data showing aztreonam-avibactam activity against >90% of New Delhi MBL-producing Enterobacterales. If aztreonam-avibactam or cefiderocol are unavailable, treatment options are limited to co-administration of antimicrobials. Regional differences made it difficult to achieve unanimous consensus across all survey questions due to differences in patient factors, local epidemiology and testing availability.
Conclusions
The Delphi panel reached consensus on optimal management of MBL-producing Enterobacterales, confirming need for targeted MBL treatment, with monotherapy preferred where available.
Autor:innen und Institutionen
- The National Institute of Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- RTI Health Solutions, Cascais, Portugal.
- Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Medical and Surgical Specialties - Infectious Diseases Unit, University of Pisa, Pisa, Italy.
- Antimicrobial Resistance Institute of São Paulo (ARIES), Universidade Federal de São Paulo, São Paulo, Brazil.
- Department of Infectious Medicine, Jena University Hospital, Jena, Germany.
ORCID-Profile: George L Daikos, Marco Falcone, Ana Cristina Gales, Stefan Hagel, Ali S Omrani, Paula Ramirez, Minggui Wang, Christopher John Little, Andy Townsend
Förderung
- Pfizer Inc.
Zitieren
APA
Carmeli, Y., Price, M., Daikos, G. L., Falcone, M., Gales, A. C., Hagel, S., Omrani, A. S., Ramirez, P., Todi, S., Wang, M., Gheorghe, M., Hauber, B., Little, C. J., & Townsend, A. (2026). Management of metallo-β-lactamase-producing Enterobacterales infections: a modified Delphi study. JAC-Antimicrobial Resistance, 8(1). https://doi.org/10.1093/jacamr/dlag030
Vancouver
Carmeli Y, Price M, Daikos GL, Falcone M, Gales AC, Hagel S, et al. Management of metallo-β-lactamase-producing Enterobacterales infections: a modified Delphi study. JAC-Antimicrobial Resistance. 2026;8(1). doi:10.1093/jacamr/dlag030
BibTeX
@article{Carmeli2026,
author = {Carmeli, Yehuda and Price, Mark and Daikos, George L and Falcone, Marco and Gales, Ana Cristina and Hagel, Stefan and Omrani, Ali S and Ramirez, Paula and Todi, Subhash and Wang, Minggui and Gheorghe, Maria and Hauber, Brett and Little, Christopher John and Townsend, Andy},
title = {Management of metallo-β-lactamase-producing Enterobacterales infections: a modified Delphi study},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/jacamr/dlag030}
}
EUVIMED